Janssen Reminyl Post-Approval Plans Include Trials In Three New Indications
This article was originally published in Pharmaceutical Approvals Monthly
Janssen’s post-approval plans for its Alzheimer’s agent Reminyl include clinical studies to support three new indications, a head-to-head trial against the market leader (Pfizer/Eisai’s Aricept), and data to support a label claim for a dual mechanism of action.
You may also be interested in...
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011
The paradoxical finding that Dendreon's cancer immunotherapeutic Provenge (sipuleucel-T) improved overall survival in men with metastatic castration-resistant prostate cancer but did not appear to slow the progression of the disease is raising questions about the future of clinical development for the burgeoning class